Methamphetamine associated psychosis and treatment with risperidone and halopridol
Phase 2
- Conditions
- Methamphetamine-associated psychosis.Mental and behavioural disorders due to use of other stimulants, including caffeine
- Registration Number
- IRCT201507155280N19
- Lead Sponsor
- Vice chancellor for research of University of Social Welfare and Rehabilitation Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Patient in the age range 18 to 60; signing informed consent. Exclusion criteria: presence of other psychiatric disorders; abusing of other psycho stimulant drugs; comorbid neurological disorders; mental retardation.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Methamphetamine-associated psychosis. Timepoint: Baseline, the first week after intervention, the second week after intervention, the third week after intervention, the first week after finishing the intervention. Method of measurement: Scale of Assessment of Positive Symptoms (SAPS).
- Secondary Outcome Measures
Name Time Method